Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset CNC
Coverage 92,334 Raw stories ingested 7,957 rewritten in CS_CZ • 0 to rewrite (last 2 days).
Agents 7 waiting Pipeline agents
  • FMP Stock News Fetch every minute 42s ago
  • FMP Forex News Fetch every 5 min 3m ago
  • CoinGecko News Fetch every 5 min 3m ago
  • FIO Stock News Fetch every 10 min 2m ago
  • Patria Stock News Fetch every 10 min 2m ago
  • Editorial rewrite Rewrite every minute 42s ago
  • Asset sync Assets every 1 hour 22m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Language
Relevance
Clear
Details Date Content Source Relevance
2026-07-22 18:16 3d ago
2026-07-22 12:46 3d ago
Centene čeká zisk na akcii 89 centů a vyšší marže
CNC Centene
FMP Stock News 78
Original source text
Key Takeaways Centene is set to report Q2 2026 results on July 28, with EPS estimated at 89 cents on $47.53B revenue.CNC's profitability may improve from pricing, cost controls and portfolio optimization amid membership falls.The health benefits ratio is projected to improve to 91.5% from 93%, supporting margins. Healthcare plan provider Centene Corporation (CNC - Free Report) is set to report second-quarter 2026 results on July 28, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at 89 cents per share on revenues of $47.53 billion. 

The second-quarter earnings estimate remained stable over the past 60 days. The bottom-line projection indicates a year-over-year improvement from a loss of 16 cents per share. However, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year decline of 2.5%.

Image Source: Zacks Investment Research

For 2026, the Zacks Consensus Estimate for Centene’s revenues is pegged at $190.97 billion, implying a fall of 2% year over year. Yet, the consensus mark for 2026 EPS is pegged at $3.46, signaling a growth of 66.4% year over year.

Centenebeat earnings estimates in three of the last four quarters and missed once, with the average surprise being 74.9%. This is depicted in the figure below.

Q2 Earnings Whispers for CenteneOur proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.

CNC has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

You can see the complete list of today’s Zacks #1 Rank stocks here.

What’s Shaping Centene’s Q2 Results?The Zacks Consensus Estimate for the company’s total commercial memberships indicates a 39.1% year-over-year decrease, primarily due to a decline in the commercial marketplace. The consensus estimate for the company’s total Medicaid memberships indicates a 4.6% decline from a year ago.

As such, the Zacks Consensus Estimate for total membership indicates a 7.6% year-over-year decline, which reflects its portfolio optimization efforts. However, the consensus mark for Medicare PDP memberships signals 12.1% growth from the year-ago quarter.

The consensus estimate projects the company’s premium growth at only 1.8% year over year. The consensus mark for the company’s investment and other income indicates a 3.2% year-over-year decline from $371 million. Moreover, the projection for service revenues indicates a 0.6% fall from the year-ago quarter’s $727 million. These are likely to have affected the second quarter top line.

Nevertheless, due to its cost-curbing efforts, better pricing and portfolio optimization, the bottom line is likely to have improved. The Zacks Consensus Estimate for the total health benefits ratio is pegged at 91.5%, down from 93% in the year-ago period, meaning a higher portion of premiums remaining in hand after paying claims.

CNC’s Price Performance & ValuationCentene's stock has gained 64.3% in the year-to-date period compared with the industry’s growth of 31%. Its peers, such as Humana Inc. (HUM - Free Report) and Molina Healthcare, Inc. (MOH - Free Report) , have jumped 57.9% and 30.5%, respectively, during this time. Meanwhile, the S&P 500 has only increased 9.5%.

YTD Price Performance – CNC, HUM, MOH, Industry & S&P 500 Image Source: Zacks Investment Research

Now, let’s look at the value Centene offers investors at current levels.

CNC is trading at 16.91X forward 12-month earnings, above its five-year median of 11.31X. But it is still below the industry’s average of 18.12X. In comparison, Humana and Molina Healthcare are currently trading at 31.75X and 31.80X, respectively.

Image Source: Zacks Investment Research

How Should You Play CNC Stock Now?The company has made meaningful progress in restoring profitability through disciplined pricing, portfolio optimization and cost-control initiatives following last year's setback. A healthier medical benefit ratio, stronger cash generation and improving performance in its Medicaid and Medicare businesses provide reasons for optimism, while the stock's sharp year-to-date rally reflects growing investor confidence in the turnaround.

However, expectations have also become more demanding. Membership declines tied to portfolio optimization are likely to weigh on revenue growth, and Centene remains exposed to policy changes affecting government-sponsored healthcare programs. Elevated operating costs, despite signs of moderation, and below-average capital efficiency also suggest that the turnaround is still a work in progress.

Given these factors, existing shareholders may prefer to hold the stock and monitor management's commentary on medical costs, reimbursement trends and membership growth after the earnings release. New investors, meanwhile, may benefit from waiting for greater clarity on the company's execution and full-year outlook before initiating positions.
2026-07-14 18:07 11d ago
2026-07-14 13:50 11d ago
Centene zvýšila výhled tržeb a výnosů z pojistného a služeb na rok 2026
CNC Centene
FMP Stock News 78
Original source text
Key Takeaways Centene has surged 66% YTD as improving execution, margins and outlook fueled its turnaround.CNC raised 2026 premium and service revenue guidance after a stronger first-quarter performance.Centene still faces policy, cost and competition risks despite stronger cash flow and profitability. Centene Corporation (CNC - Free Report) , one of the largest managed healthcare providers in the United States, has staged an impressive comeback in 2026. The stock has surged 66% year to date, far ahead of the industry’s  28.5% gain. The broader S&P 500 has advanced 10.7% over the same period, while UnitedHealth Group Incorporated (UNH - Free Report) and Elevance Health, Inc. (ELV - Free Report) have returned 30% and 21.3%, respectively.

The rally marks a sharp reversal from last year's selloff, when rising medical costs forced Centene to withdraw its financial guidance and shook investor confidence. Since then, the company has regained visibility into its business, restored earnings growth and convinced investors that its turnaround is gaining traction. Better execution, improving profitability and a more favorable outlook for managed care have all helped drive the stock higher.

YTD Price Performance: CNC, UNH, ELV, Industry & S&P 500 Image Source: Zacks Investment Research

The first quarter reflected that progress. Centene's health benefits ratio improved 20 basis points from the prior-year period to 87.3%, while premium revenues increased 5.2% year over year to $43.9 billion, supported by higher Prescription Drug Plan (PDP) enrollment and stronger Medicaid reimbursement rates. The balance sheet also improved, with long-term debt declining 6% from year-end 2025 to $16.3 billion. Encouraged by these trends, management raised its 2026 premium and service revenue guidance to a range of $171-$175 billion from the previous outlook of $170-$174 billion.

What Do the Estimates Say Now?The Zacks Consensus Estimate for 2026 earnings is pegged at $3.46 per share, representing a 66.4% increase from the prior year. Analysts expect another year of growth in 2027, with earnings projected to reach $4.41 per share.

Revenue tells a different story. Estimates call for revenues of $191.03 billion in 2026, down 1.9% year over year, followed by a slight decline to $190.33 billion in 2027. Even so, investors appear focused on margin improvement rather than top-line growth.

Centene has beaten earnings estimates in three of the past four quarters, delivering an average surprise of 74.9%.

CNC’s ValuationCentene's strong share price performance has naturally lifted its valuation. The stock now trades at a forward price-to-earnings multiple of 17.22X, well above its five-year median of 11.31X. However, it still trades below the industry average of 18.48X. Compared with UnitedHealth at 21.84X and Elevance at 15.15X, Centene sits somewhere in the middle and carries a Value Score of A, suggesting the stock still offers a reasonable balance between price and earnings potential.

Image Source: Zacks Investment Research

Challenges Still Deserve AttentionDespite the recovery, several risks remain. Centene generates most of its revenues from government-sponsored healthcare programs, leaving results closely tied to changes in federal and state policies. Medicaid, Medicare and Affordable Care Act Marketplace plans all depend on reimbursement rates, funding decisions and evolving regulations.

Costs also remain a concern. Total operating expenses increased 5.5% in 2023, 5.8% in 2024 and 26.6% in 2025. During the first quarter of 2026, operating expenses rose another 6.6% year over year. Although management continues to adjust pricing and tighten cost controls, elevated medical costs and ongoing investments could slow the pace of margin improvement.

Capital efficiency also trails peers. Centene's trailing 12-month return on invested capital stands at 4.5%, below the industry average of 5.5%, suggesting there is still room to improve how the company deploys capital.

What Is Working in CNC’s Favor?Several factors continue to strengthen Centene's long-term outlook. Total membership eased to 26.3 million at the end of the first quarter as the company reshaped its portfolio, but growth is shifting toward businesses with better profitability. PDP membership increased 11.6% year over year, while Medicare Advantage and Dual-Eligible Special Needs Plan retention improved.

The Medicaid business remains another important driver. Improving state reimbursement rates and disciplined pricing are helping lift profitability in one of Centene's largest operations, although competition for new government contracts remains intense.

Management is also focused on improving efficiency. The merger of Carolina Complete Health and WellCare of North Carolina into a single provider-led organization creates a combined business serving more than 980,000 members, including more than 775,000 Medicaid members. The move should deepen relationships with providers while improving care coordination.

Cash generation has strengthened as earnings recover. Net cash from operations climbed to $4.4 billion in the first quarter from $1.5 billion a year earlier. Combined with favorable demographic trends, including an aging population and rising chronic disease rates, this gives Centene a stronger foundation for sustained growth.

Should Investors Buy CNC Stock Now?Centene has made meaningful progress in rebuilding investor confidence after a difficult 2025. Improving margins, cash generation, balance sheet and an encouraging earnings outlook suggest that the turnaround is gaining momentum. At the same time, the company continues to face familiar challenges, including policy uncertainty, elevated medical costs and intense competition across government-sponsored healthcare programs.

While the stock's sharp rally has reduced some of its valuation appeal, it still trades below the industry average and offers solid long-term fundamentals. With both positive catalysts and lingering risks in play, investors may want to wait for additional evidence of sustained earnings improvement. Centene currently carries a Zacks Rank #3 (Hold), indicating that existing shareholders can stay invested, while new investors may consider waiting for a more attractive entry point. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
2026-07-09 13:23 16d ago
2026-07-09 07:00 17d ago
Meridian získala čtyřletou smlouvu na Illinois Medicaid od roku 2027
CNC Centene
FMP Stock News 78
Original source text
, /PRNewswire/ -- Centene Corporation (Centene) (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its Illinois subsidiary, Meridian Health Plan of Illinois, Inc. (Meridian), has been selected by the Illinois Department of Healthcare and Family Services (HFS) to continue providing services for the HealthChoice Illinois Medicaid managed care program. The four-year contract is expected to begin January 1, 2027, through 2030.

Meridian logo "Centene has a long track record serving Medicaid and dually eligible Medicaid-Medicare members in Illinois," said Chief Executive Officer Sarah M. London. "This award reflects Meridian's strong local partnerships and focus on delivering coordinated, high-quality care while connecting people to the support they need beyond the clinical setting. We value our partnership with the state and look forward to continuing to expand access and strengthen outcomes across Illinois."

Meridian is one of six managed care organizations selected by HFS to deliver access to high-quality managed care services to approximately 2.4 million Medicaid-eligible Illinoisans statewide. As of May 2026, Meridian serves more than 596,000 Medicaid enrollees through the HealthChoice Illinois Medicaid program. Under the new contract, Meridian will continue providing managed care for Medicaid enrollees, including access to integrated primary, maternal, and behavioral health care.

"We are honored to be chosen again by the Illinois Department of Healthcare and Family Services to continue delivering access to high-quality, whole person care through proven performance and building on our strategy to address barriers to care," said Meridian Plan President and Chief Executive Officer Cristal Gary.

In addition to ensuring its members get the medical care they need through its clinical and population health programs, Meridian's whole-person approach also focuses on improving well-being by working with community-based partners to address gaps in social drivers that impact health outcomes. Meridian is recognized for its work with the highest possible 5-star rating in the latest 2024 HealthChoice Illinois Report Card in three critical areas: Access to Care, Living with Illness, and Women's/Children's Health.

Building on nearly 20 years of experience serving Illinois communities, Meridian will continue providing comprehensive, coordinated care for some of the state's most vulnerable populations while advancing programs that address social drivers of health across all 102 counties.

About Centene Corporation 
Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach with local teams to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured individuals. Centene offers affordable and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace. 

Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, http://investors.centene.com/.

About Meridian Health Plan of Illinois
Meridian Health Plan of Illinois, Inc. and its family of health plans provide government-sponsored managed care to families, children, seniors, and individuals with complex medical needs. This includes Meridian's Medicaid and Medicare-Medicaid plans, and YouthCare HealthChoice Illinois. YouthCare is a specialized program designed to address the healthcare needs of Illinois Department of Children and Family Services (DCFS) youth in out-of-home placement and former youth in care. Meridian connects members to care and offers comprehensive services to support lifelong health and wellness. Meridian is a company of Centene Corporation, a leading healthcare enterprise committed to helping people live healthier lives. Learn more at ILmeridian.com.

All statements, other than statements of current or historical fact, contained in this press release are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "predict," "intend," "seek," "target," "goal," "potential," "may," "will," "would," "could," "should," "can," "continue," and other similar words or expressions (and the negative thereof). Centene Corporation and its subsidiaries (Centene, the Company, our or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our expected future operating or financial performance, changes in laws and regulations, market opportunity, expectations concerning pricing actions, competition, expected contract start dates and terms, expected activities in connection with completed and future acquisitions and dispositions, our investments, and the adequacy of our available cash resources. These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments, and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive, and other factors that may cause our or our industry's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions. All forward-looking statements included in this press release are based on information available to us on the date hereof. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this press release, whether as a result of new information, future events, or otherwise, after the date hereof. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables, and events including, but not limited to: our ability to design and price products that are competitive and/or actuarially sound; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical costs; rate cuts, insufficient rate changes or other payment reductions or delays by government payors affecting our government businesses; the effect of social, economic, and political conditions, geopolitical events and state and federal policies, including the amount and terms of state and federal funding for government-sponsored healthcare programs, including as a result of changes in U.S. presidential administrations or Congress; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively referred to as the ACA) and any regulations enacted thereunder, including the timing and terms of renewal or modification of the Enhanced Advance Premium Tax Credits (eAPTCs) or program integrity initiatives that could have the effect of reducing membership or profitability of our products; unanticipated increased healthcare costs, including due to changes in consumer and provider behaviors, inflation and tariffs; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that could impact revenue and future growth; competition, including for providers, broker distribution networks, contract reprocurements and organic growth; our ability to adequately anticipate demand and timely provide for operational resources to maintain service level requirements in compliance with the terms of our contracts and state and federal regulations; our ability to comply with the terms of our contracts and state and federal regulations and our ability to effectively oversee our third-party vendors to comply with the terms of their contracts with us and state and federal regulations; our ability to manage our information systems effectively; disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in our relationships with third-party vendors; impairments to real estate, investments, goodwill and intangible assets; changes in senior management, loss of one or more key personnel or an inability to attract, hire, integrate and retain skilled personnel; membership and revenue declines or unexpected trends; changes in healthcare practices, new technologies, and advances in medicine; our ability to effectively and ethically use artificial intelligence and machine learning in compliance with applicable laws; changes in macroeconomic conditions, including inflation, interest rates and volatility in the financial markets; negative public perception of the Company and the managed care industry; uncertainty concerning government shutdowns, debt ceilings or funding; tax matters; disasters, climate-related incidents, acts of war or aggression or major epidemics; changes in expected contract start dates and terms; changes in provider, broker, vendor, state, federal and other contracts and delays in the timing of regulatory approval of contracts, including due to protests and our ability to timely comply with any such changes to our contractual requirements or manage any unexpected delays in regulatory approval of contracts; the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare or other customers); the difficulty of predicting the timing or outcome of legal or regulatory audits, investigations, proceedings or matters including, but not limited to, our ability to resolve claims and/or allegations on acceptable terms, or at all, or whether additional claims, reviews or investigations will be brought; challenges to our contract awards; cyber-attacks or other data security incidents or our failure to comply with applicable privacy, data or security laws and regulations; the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the terms of our contracts and the undertakings in connection with any regulatory, governmental, or third party consents or approvals for acquisitions or dispositions; any changes in expected closing dates, estimated purchase price, or accretion for acquisitions or dispositions; losses in our investment portfolio; restrictions and limitations in connection with our indebtedness; a downgrade of our corporate family rating, issuer rating or credit rating of our indebtedness; the availability of debt and equity financing on terms that are favorable to us and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission (SEC). This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition, and results of operations, in our filings with the SEC, including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future medical and selling, general and administrative (SG&A) costs.

SOURCE Centene Corporation
2026-07-06 15:53 19d ago
2026-07-06 11:16 19d ago
Centene zvyšuje zisk na akcii a výhled díky AI proti podvodům
CNC Centene
FMP Stock News 78
Original source text
Key Takeaways Centene is expanding AI-enabled fraud detection and payment integrity to improve medical cost efficiency.CNC improved Medicaid health benefits ratio to 93.1% as adjusted EPS rose 16.2% YoY in Q1 2026.Centene raised 2026 adjusted EPS guidance to more than $3.40 after a stronger first quarter. Centene Corporation (CNC - Free Report) is intensifying its efforts to curb fraud, waste and abuse as part of a broader strategy to improve profitability across its government-sponsored healthcare businesses. The company is expanding payment integrity capabilities by combining advanced analytics with AI-enabled tools to identify suspicious billing patterns, abnormal claims activity and emerging medical cost trends earlier. These initiatives are likely supporting CNC in strengthening cost controls while protecting taxpayer-funded healthcare programs.

The strategy is gaining traction in Medicaid, where the company has enhanced oversight of providers, particularly in applied behavior analysis services, while advocating program reforms that would allow states to take a more proactive approach to fraud prevention. Its ongoing investments in utilization management, network optimization and clinical programs create a multi-layered framework to improve medical cost efficiency. These efforts contributed to continued progress in Medicaid margins during the first quarter of 2026.

In the first quarter of 2026, adjusted earnings per share (EPS) rose 16.2% year over year to $3.37. Medicaid's health benefits ratio improved 50 bps year over year to 93.1%, reflecting better medical cost management and ongoing operational improvements. Encouraged by the strong start, Centene raised its 2026 adjusted EPS guidance to more than $3.40 from above $3.00 previously.

While healthcare cost trends remain challenging, Centene's growing focus on fraud prevention, payment integrity and AI-driven analytics could strengthen margin recovery over time. If execution remains consistent, these initiatives may provide a durable competitive advantage while supporting sustainable earnings growth.

How Are Competitors Faring?Some of CNC’s major competitors in the healthcare service provider space are UnitedHealth Group Incorporated (UNH - Free Report) and Elevance Health, Inc. (ELV - Free Report) .

UnitedHealth Group continues to strengthen payment integrity through advanced analytics, AI-driven claims monitoring and Optum's data capabilities. In the first quarter of 2026, UNH’s medical care ratio improved 90 bps year over year to 83.9%. The company remains focused on detecting billing irregularities, improving claims accuracy and managing medical costs, supporting long-term operational efficiency.

Elevance Health is enhancing fraud prevention by leveraging predictive analytics, automation and provider oversight to improve payment integrity. ELV is investing in data-driven care management and claims review capabilities, helping control medical costs while improving program integrity across its government-sponsored health plans.

Centene’s Price Performance, Valuation & EstimatesShares of CNC have surged 64.9% in the year-to-date period compared with the industry’s rise of 28.4%.

Image Source: Zacks Investment Research

From a valuation standpoint, Centene trades at a forward price-to-earnings ratio of 17.24, below the industry average of 18.52. CNC carries a Value Score of A.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $3.46 per share, implying 66.4% growth from the year-ago period.

Image Source: Zacks Investment Research

CNC stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
2026-07-02 18:28 23d ago
2026-07-02 12:01 23d ago
Centene zvýšila upravený EPS a výhled na rok 2026
CNC Centene
FMP Stock News 78
Original source text
Key Takeaways CNC's integrated healthcare model supports earnings through coordinated care, pharmacy and clinical services.CNC raised its 2026 adjusted EPS guidance after Q1 adjusted EPS rose 16.2% YoY and revenues increased 5.1%.Centene is expanding AI, analytics and value-based care to improve costs, pricing and care quality. Centene Corporation's (CNC - Free Report) integrated healthcare model is supporting its earnings potential by combining government-sponsored health plans with coordinated clinical services, pharmacy benefits and community-based care. This approach helps the company to manage medical costs more effectively while improving health outcomes across Medicaid, Medicare and Commercial members. As of March 31, 2026, Centene served 26.3 million members, giving the company significant scale to spread administrative costs and support operating leverage.

Centene is also sharpening its operational capabilities through technology and data-driven initiatives. It expanded the use of advanced analytics and selective AI-enabled tools across medical economics, forecasting, fraud detection and payment integrity. These initiatives are helping identify emerging healthcare trends earlier, strengthen claims oversight and improve pricing decisions. In Medicare, the company continues to simplify provider contracts and expand value-based care models targeting high-cost specialties, supporting better quality and lower total cost of care.

In the first quarter of 2026, adjusted earnings per share increased 16.2% year over year to $3.37, while premium and service revenues rose 5.1%. Medicaid's health benefits ratio improved 50 bps year over year to 93.1%, reflecting the impact of better reimbursement, disciplined medical cost management and ongoing operational improvements. Encouraged by the strong start, Centene raised its 2026 adjusted EPS guidance to more than $3.40.

However, regulatory changes and medical cost trends remain key challenges. CNC's integrated approach is creating a stronger operating foundation. Continued investments in technology, clinical programs and provider partnerships should support margin recovery and position the company for sustainable earnings growth over the long term.

How Are Competitors Faring?Some of CNC’s major competitors in the value-based care space are UnitedHealth Group Incorporated (UNH - Free Report) and Elevance Health, Inc. (ELV - Free Report) .

UnitedHealth continues to strengthen its integrated healthcare platform by combining UnitedHealthcare's insurance operations with Optum's pharmacy, care delivery and health services businesses. This connected model enhances care coordination, improves operational efficiency and supports UNH’s long-term earnings growth through diversified revenue streams.

Elevance Health is expanding its integrated care strategy through Carelon, which combines pharmacy, behavioral health and care management services. ELV is leveraging these capabilities to improve clinical outcomes, manage medical costs more effectively and support sustainable earnings growth across its government-sponsored and commercial businesses.

Centene’s Price Performance, Valuation & EstimatesShares of CNC have rallied 66.1% in the year-to-date period compared with the industry’s rise of 36.5%.

Image Source: Zacks Investment Research

From a valuation standpoint, Centene trades at a forward price-to-earnings ratio of 17.39, below the industry average of 19.69. CNC carries a Value Score of A.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $3.46 per share, implying 66.4% growth from the year-ago period.

Image Source: Zacks Investment Research

CNC stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
2026-06-24 16:08 1mo ago
2026-06-24 06:45 1mo ago
Canada Nickel jmenovala SB1 Markets financováním až do výše 600 milionů USD
CNC Centene
FMP Stock News 78
Original source text
, /PRNewswire/ - Canada Nickel Company Inc. ("Canada Nickel" or the "Company") (TSXV: CNC) (OTCQX: CNIKF) has appointed SB1 Markets AS ("SB1 Markets") as exclusive advisor to arrange debt financing of up to US$600 million. The facility would allow the Company to monetize Investment Tax Credits expected to be generated by the construction of its Crawford Nickel Project.  The Company expects the financing to be arranged by the end of 2026, in advance of a final investment decision on Crawford targeted for 2027. There can be no assurance that the proposed financing will be completed, and, if completed, the terms of such financing would be included in a subsequent release.

Mark Selby, CEO and Director of Canada Nickel Company said, "We are very pleased to work with SB1 Markets, a global leader with deep experience and a highly successful track record in providing debt financing for natural resource projects.  With a final permitting decision expected shortly, we can now move more aggressively on key components of our project financing as we advance towards a final investment decision.  This bridge financing is central to Crawford's overall capital structure; it allows us to deploy Canada's generous investment tax credits available for critical mineral projects in Canada to fund more than half of the equity capital we need to build Crawford."

About SB1 Markets

SB1 Markets AS is a leading Nordic investment bank, jointly owned by SpareBank 1 and Swedbank and providing investment banking services across DCM, ECM, advisory, research, sales, corporate access, and FICC. The firm is headquartered in Norway and Sweden with around 270 professionals. SB1 Markets has arranged transactions for a total value of approximately USD 70bn over the last twelve months and financing natural resource companies and projects is a core part of the company's business.

About Canada Nickel

Canada Nickel is advancing the next generation of nickel-sulphide projects to deliver nickel required to feed the high growth electric vehicle and stainless steel markets. Canada Nickel has applied in multiple jurisdictions to trademark the terms NetZero NickelTM, NetZero CobaltTM and NetZero IronTM and is pursuing the development of processes to allow the production of net zero carbon nickel, cobalt, and iron products. Canada Nickel provides investors with leverage to nickel in low political risk jurisdictions. Canada Nickel is currently anchored by its 100% owned flagship Crawford Nickel-Cobalt Sulphide Project in the heart of the prolific Timmins-Cochrane mining camp. For more information, please visit www.canadanickel.com.

For further information, please contact:

Mark Selby
CEO
Phone: 647-256-1954
Email: [email protected]

Cautionary Statement Concerning Forward-Looking Statements

This press release contains certain information that may constitute "forward-looking information" under applicable Canadian securities legislation. Forward looking information includes the ability of the Company to qualify for critical minerals tax credits, complete the financing described in this release and otherwise finance and construct the Crawford Nickel Project, deliver nickel required to feed the high growth electric vehicle and stainless steel markets, and the development of processes to allow the production of net zero carbon nickel, cobalt, and iron products. Readers should not place undue reliance on forward looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canada Nickel to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. There are no assurances that Crawford will be placed into production. Factors that could affect the outcome include, among others: inability to repay the loan or comply with the covenants set out in the loan agreement; the ability to obtain the approval of the TSX Venture Exchange for the matters described herein; the actual results of development activities; project delays; inability to raise the funds necessary to complete development; general business, economic, competitive, political and social uncertainties; future prices of metals or project costs could differ substantially and make any commercialization uneconomic; availability of alternative nickel sources or substitutes; actual nickel recovery; conclusions of economic evaluations; changes in applicable laws; changes in project parameters as plans continue to be refined; accidents, labour disputes, the availability and productivity of skilled labour and other risks of the mining industry; political instability, terrorism, insurrection or war; delays in obtaining governmental approvals, necessary permitting or in the completion of development or construction activities; mineral resource estimates relating to Crawford could prove to be inaccurate for any reason whatsoever; additional but currently unforeseen work may be required to advance to the feasibility stage; and even if Crawford goes into production, there is no assurance that operations will be profitable. Although Canada Nickel has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date of this news release and Canada Nickel disclaims any obligation to update any forward looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Canada Nickel Company Inc.